These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31202896)

  • 21. A randomized controlled clinical trial on piperacillin/tazobactam versus ticarcillin/clavulanic acid for the treatment of bacterial infections.
    Hou F; Li J; Gao L; Chen Y
    Chin Med J (Engl); 1998 Nov; 111(11):1039-43. PubMed ID: 11189212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Piperacillin, beta-lactam inhibitor plus gentamicin as empirical therapy of a sequential regimen in febrile neutropenia of pediatric cancer patients.
    Fleischhack G; Schmidt-Niemann M; Wulff B; Havers W; Marklein G; Hasan C; Bode U
    Support Care Cancer; 2001 Jul; 9(5):372-9. PubMed ID: 11497392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
    Xiao YH; Hu YJ
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
    [No Abstract]   [Full Text] [Related]  

  • 24. [Evaluation of in vitro susceptibility of hospital bacterial isolates to piperacillin and tazocin (piperacillin/tazobactam].
    Birawska I; Fuchs J; Szulakowska E
    Med Dosw Mikrobiol; 1998; 50(1-2):41-6. PubMed ID: 9857612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.
    Young M; Plosker GL
    Pharmacoeconomics; 2001; 19(11):1135-75. PubMed ID: 11735679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stability of piperacillin sodium-tazobactam sodium and ranitidine hydrochloride in 0.9% sodium chloride injection during simulated Y-site administration.
    Choi JS; Burm JP; Jhee SS; Chin A; Ulrich RW; Gill MA
    Am J Hosp Pharm; 1994 Sep; 51(18):2273-6. PubMed ID: 7801988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Piperacillin/tazobactam: a critical review of the evolving clinical literature.
    Sanders WE; Sanders CC
    Clin Infect Dis; 1996 Jan; 22(1):107-23. PubMed ID: 8824974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative in vitro activity of piperacillin, piperacillin-sulbactam and piperacillin-tazobactam against nosocomial pathogens isolated from intensive care patients.
    Frank U; Mutter J; Schmidt-Eisenlohr E; Daschner FD
    Clin Microbiol Infect; 2003 Nov; 9(11):1128-32. PubMed ID: 14616732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is high-dose β-lactam therapy associated with excessive drug toxicity in critically ill patients?
    McDonald C; Cotta MO; Little PJ; McWhinney B; Ungerer JP; Lipman J; Roberts JA
    Minerva Anestesiol; 2016 Sep; 82(9):957-65. PubMed ID: 27054905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Piperacillin-tazobactam versus ciprofloxacin plus amoxicillin in the treatment of infective episodes after liver transplantation.
    Philpott-Howard J; Burroughs A; Fisher N; Hastings M; Kibbler C; Mutimer D; Patch D; Rolando N; Wade J; Wendon J; O'Grady J
    J Antimicrob Chemother; 2003 Dec; 52(6):993-1000. PubMed ID: 14585863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro activity of piperacillin/tazobactam against recent clinical isolates from hospitalized patients in ten Belgian hospitals.
    Verbist L; Dhoore P
    Acta Clin Belg; 1995; 50(5):274-81. PubMed ID: 8533527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro susceptibility of multi-drug resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolated from clinical specimens at Bugando Medical Centre, Tanzania to Piperacillin-Tazobactam.
    Petro D; Mushi MF; Moremi N; Iddi S; Mirambo M; Seni J; Mshana SE
    Tanzan J Health Res; 2014 Jan; 16(1):54-7. PubMed ID: 26867273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In-vitro activity of piperacillin and tazobactam combination against clinically significant bacteria.
    Obi CL; Makandiramba B; Robertson V; Tswana SA; Moyo SR; Nziramasanga P
    East Afr Med J; 1998 Mar; 75(3):162-5. PubMed ID: 9640815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicenter evaluation of the in vitro activity of piperacillin-tazobactam compared with eleven selected beta-lactam antibiotics and ciprofloxacin against more than 42,000 aerobic gram-positive and gram-negative bacteria. In Vitro Susceptibility Surveillance Group.
    Murray PR; Cantrell HF; Lankford RB
    Diagn Microbiol Infect Dis; 1994 Jun; 19(2):111-20. PubMed ID: 7805355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative activity of piperacillin/tazobactam against 5625 isolates from hospitalised patients. Multicentre Study Group.
    Verbist L; Verhaegen J; Wouters C; Vandenhoven G
    J Antimicrob Chemother; 1996 Feb; 37(2):285-93. PubMed ID: 8707738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Shelf lives of aseptically prepared medicines--stability of piperacillin/tazobactam in PVC and non-PVC bags.
    Rigge DC; Jones MF
    J Pharm Biomed Anal; 2005 Sep; 39(1-2):339-43. PubMed ID: 16085149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stability of piperacillin sodium-tazobactam sodium in polypropylene syringes and polyvinyl chloride minibags.
    Moon YS; Chung KC; Chin A; Gill MA
    Am J Health Syst Pharm; 1995 May; 52(9):999-1001. PubMed ID: 7641040
    [No Abstract]   [Full Text] [Related]  

  • 39. Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.
    Nicasio AM; VanScoy BD; Mendes RE; Castanheira M; Bulik CC; Okusanya OO; Bhavnani SM; Forrest A; Jones RN; Friedrich LV; Steenbergen JN; Ambrose PG
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2075-80. PubMed ID: 26787689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of piperacillin/tazobactam in intra-abdominal infections.
    Vestweber KH; Grundel E
    Eur J Surg Suppl; 1994; (573):57-60. PubMed ID: 7524797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.